<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656630</url>
  </required_header>
  <id_info>
    <org_study_id>AA012602</org_study_id>
    <secondary_id>R01AA012602</secondary_id>
    <nct_id>NCT00656630</nct_id>
  </id_info>
  <brief_title>Medication Development in Alcoholism: Acamprosate Versus Naltrexone</brief_title>
  <official_title>Medication Development in Protracted Abstinence in Alcoholism: Acamprosate Versus Naltrexone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Scripps Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Scripps Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop and validate a human laboratory model for prediction
      of medication efficacy in clinical trials for relapse prevention in alcohol dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, 3-cell, outpatient human laboratory study to determine the degree to
      which acamprosate and naltrexone will suppress subjective and physiological responsivity to
      alcohol cues relative to placebo in early abstinence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Acamprosate or Naltrexone or Placebo During the Double-Blind Period</measure>
    <time_frame>1 week</time_frame>
    <description>The four Visual Analog Scale questions assess domains of alcohol craving: the intention to drink, loss of control, relief craving, and urge intensity. The scale ranges from 0-20 where a zero indicates no craving and 20 indicates severe craving; thus, a higher score indicates a worse outcome. Total is a summation of the four subscales (i.e. Strength, Intent, Impulse, Relief) and ranges in value from 0-80 with higher scores indicative of a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Standard Drinks Per Week at 1 Week</measure>
    <time_frame>1 week</time_frame>
    <description>Standard drinks are equivalent to 14 grams of pure alcohol and number of drinks are assessed with Timeline Follow-Back (TLFB) methods. Change = (Week 1 - Baseline). More negative values indicate less use of alcohol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mood on the Beck Depression Inventory (BDI-II) at Week 1</measure>
    <time_frame>1 week</time_frame>
    <description>The BDI-II is a self-rating of severity of depressive symptoms. BDI-II Total scores range from 0-63; a lower score indicates less severe depressive systems and thus is a better outcome. Change = (Week 1 score - Baseline score). The Total score is a sum of the 21 items on the BDI-II instrument, with each item rated from 0-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sleep Quality on the Pittsburgh Sleep Quality Index (PSQI) Total Score at Week 1</measure>
    <time_frame>1 week</time_frame>
    <description>The PSQI is an instrument to assess subjective sleep quality and disturbance. The Total score ranges from 0 to 21 where a lower score is better sleep quality. Change = (Week 1 score - Baseline score). Seven subscales (range 0-3) are summed to compute the Total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Screening in Craving on the Alcohol Craving Questionnaire-Short Form (ACQ-SF) Total Score at Week 1</measure>
    <time_frame>2 weeks</time_frame>
    <description>The ACQ-SF is an assessment of current drinking urges, difficulty resisting urge and anticipation of positive outcome or relief from negative state by drinking. The Total score ranges from 0 to 7 where a lower score is a better outcome. Change = (Week 1 score - Screening score). The scale is comprised of twelve items (range 0-7) that are averaged to compute the Total score.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acamprosate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acamprosate</intervention_name>
    <description>Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Campral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>50mg capsule, Once daily, 1 week duration</description>
    <arm_group_label>2</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo capsule, 1 week duration</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females ≥ 18 and ≤ 55 years of age

          -  Meets Diagnostic and Statistical Manual-Fourth Edition (DSM-IV) criteria for current
             alcohol dependence

          -  Does not desire treatment

          -  Alcohol free, as verified by breath alcohol concentration, with a Clinical Institute
             Withdrawal Assessment (CIWA) ≤ 8, at the time of testing, with no evidence of drinking
             for at least 3 days but no more than 7 days prior to the cue reactivity session

          -  Able to complete and understand questionnaires and study procedures in English

          -  Verbal I.Q. estimate ≥ 85

          -  Signed informed consent

        Exclusion Criteria:

          -  Currently meets DSM-IV criteria for dependence on substances other than alcohol or
             nicotine

          -  Significant medical disorders that will increase potential risk or interfere with
             study participation

          -  Sexually active women with childbearing potential who are pregnant, nursing, or refuse
             to use a reliable method of birth control

          -  Meets DSM-IV criteria for a major Axis I disorder, including depression or anxiety
             disorders

          -  Treatment within the month prior to screening with investigational medications or
             those which may influence drinking outcome, e.g., disulfiram (Antabuse), naltrexone
             (ReVia), acamprosate (Campral), antidepressants or other psychotropic agents

          -  Chronic treatment with any narcotic-containing medications during the previous month
             or evidence of current opiate use

          -  Liver function tests more than three times normal or elevated bilirubin

          -  No fixed domicile and/or no availability by telephone or beeper

          -  Current involvement in or plans for treatment prior to study completion

          -  Patients who have a history of adverse drug reactions to the study drugs or their
             ingredients

          -  Failure to take double-blind medication as prescribed

          -  Inability to understand or comply with the provisions of the protocol or consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara J Mason, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Scripps Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Scripps Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pearsoncenter.org</url>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2008</study_first_posted>
  <results_first_submitted>December 14, 2016</results_first_submitted>
  <results_first_submitted_qc>February 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2017</results_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Scripps Research Institute</investigator_affiliation>
    <investigator_full_name>Barbara J. Mason</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited for study participation at the Laboratory of Clinical Psychopharmacology at The Scripps Research Institute in La Jolla, California from 04/17/2008-12/10/2009. Sixty eight subjects were enrolled, and sixty two subjects completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Campral (Acamprosate)</title>
          <description>Acamprosate
Acamprosate: Total dose, 1998 mg daily, 1 week duration</description>
        </group>
        <group group_id="P2">
          <title>ReVia (Naltrexone)</title>
          <description>Naltrexone
Naltrexone: 50mg capsule, Once daily, 1 week duration</description>
        </group>
        <group group_id="P3">
          <title>Sugar Pill (Placebo)</title>
          <description>Placebo: Double-dummy placebo capsules, 1 week duration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Campral (Acamprosate)</title>
          <description>Acamprosate
Acamprosate: Total dose, 1998 mg daily, 1 week duration</description>
        </group>
        <group group_id="B2">
          <title>ReVia (Naltrexone)</title>
          <description>Naltrexone
Naltrexone: 50mg capsule, Once daily, 1 week duration</description>
        </group>
        <group group_id="B3">
          <title>Sugar Pill (Placebo)</title>
          <description>Placebo: Double-dummy placebo capsules, 1 week duration</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.73" spread="10.10"/>
                    <measurement group_id="B2" value="36.37" spread="12.45"/>
                    <measurement group_id="B3" value="42.84" spread="10.37"/>
                    <measurement group_id="B4" value="37.97" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Acamprosate or Naltrexone or Placebo During the Double-Blind Period</title>
        <description>The four Visual Analog Scale questions assess domains of alcohol craving: the intention to drink, loss of control, relief craving, and urge intensity. The scale ranges from 0-20 where a zero indicates no craving and 20 indicates severe craving; thus, a higher score indicates a worse outcome. Total is a summation of the four subscales (i.e. Strength, Intent, Impulse, Relief) and ranges in value from 0-80 with higher scores indicative of a worse outcome.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campral (Acamprosate)</title>
            <description>Acamprosate
Acamprosate: Total dose, 1998 mg daily, 1 week duration</description>
          </group>
          <group group_id="O2">
            <title>ReVia (Naltrexone)</title>
            <description>Naltrexone
Naltrexone: 50mg capsule, Once daily, 1 week duration</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill (Placebo)</title>
            <description>Placebo: Double-dummy placebo capsules, 1 week duration</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Acamprosate or Naltrexone or Placebo During the Double-Blind Period</title>
          <description>The four Visual Analog Scale questions assess domains of alcohol craving: the intention to drink, loss of control, relief craving, and urge intensity. The scale ranges from 0-20 where a zero indicates no craving and 20 indicates severe craving; thus, a higher score indicates a worse outcome. Total is a summation of the four subscales (i.e. Strength, Intent, Impulse, Relief) and ranges in value from 0-80 with higher scores indicative of a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strength</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="3.10"/>
                    <measurement group_id="O2" value="3.40" spread="3.87"/>
                    <measurement group_id="O3" value="5.86" spread="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="1.56"/>
                    <measurement group_id="O2" value="2.99" spread="3.67"/>
                    <measurement group_id="O3" value="4.22" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impulse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="1.94"/>
                    <measurement group_id="O2" value="1.69" spread="2.78"/>
                    <measurement group_id="O3" value="4.31" spread="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="1.67"/>
                    <measurement group_id="O2" value="2.01" spread="3.56"/>
                    <measurement group_id="O3" value="3.57" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="6.24"/>
                    <measurement group_id="O2" value="10.09" spread="12.12"/>
                    <measurement group_id="O3" value="17.96" spread="15.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Standard Drinks Per Week at 1 Week</title>
        <description>Standard drinks are equivalent to 14 grams of pure alcohol and number of drinks are assessed with Timeline Follow-Back (TLFB) methods. Change = (Week 1 - Baseline). More negative values indicate less use of alcohol.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campral (Acamprosate)</title>
            <description>Acamprosate
Acamprosate: Total dose, 1998 mg daily, 1 week duration</description>
          </group>
          <group group_id="O2">
            <title>ReVia (Naltrexone)</title>
            <description>Naltrexone
Naltrexone: 50mg capsule, Once daily, 1 week duration</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill (Placebo)</title>
            <description>Placebo: Double-dummy placebo capsules, 1 week duration</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Standard Drinks Per Week at 1 Week</title>
          <description>Standard drinks are equivalent to 14 grams of pure alcohol and number of drinks are assessed with Timeline Follow-Back (TLFB) methods. Change = (Week 1 - Baseline). More negative values indicate less use of alcohol.</description>
          <units>drinks/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drinks/week Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.90" spread="61.89"/>
                    <measurement group_id="O2" value="47.02" spread="24.08"/>
                    <measurement group_id="O3" value="48.87" spread="58.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks/week Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.37" spread="22.81"/>
                    <measurement group_id="O2" value="25.79" spread="14.32"/>
                    <measurement group_id="O3" value="21.51" spread="18.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks/week Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.53" spread="60.68"/>
                    <measurement group_id="O2" value="-21.23" spread="23.93"/>
                    <measurement group_id="O3" value="-27.35" spread="44.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mood on the Beck Depression Inventory (BDI-II) at Week 1</title>
        <description>The BDI-II is a self-rating of severity of depressive symptoms. BDI-II Total scores range from 0-63; a lower score indicates less severe depressive systems and thus is a better outcome. Change = (Week 1 score - Baseline score). The Total score is a sum of the 21 items on the BDI-II instrument, with each item rated from 0-3.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Campral (Acamprosate)</title>
            <description>Acamprosate
Acamprosate: Total dose, 1998 mg daily, 1 week duration</description>
          </group>
          <group group_id="O2">
            <title>ReVia (Naltrexone)</title>
            <description>Naltrexone
Naltrexone: 50mg capsule, Once daily, 1 week duration</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill (Placebo)</title>
            <description>Placebo: Double-dummy placebo capsules, 1 week duration</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mood on the Beck Depression Inventory (BDI-II) at Week 1</title>
          <description>The BDI-II is a self-rating of severity of depressive symptoms. BDI-II Total scores range from 0-63; a lower score indicates less severe depressive systems and thus is a better outcome. Change = (Week 1 score - Baseline score). The Total score is a sum of the 21 items on the BDI-II instrument, with each item rated from 0-3.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BDI-II Total Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="5.14"/>
                    <measurement group_id="O2" value="4.04" spread="4.33"/>
                    <measurement group_id="O3" value="3.53" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDI-II Total Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="4.81"/>
                    <measurement group_id="O2" value="3.84" spread="4.02"/>
                    <measurement group_id="O3" value="4.94" spread="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDI-II Total Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="4.16"/>
                    <measurement group_id="O2" value="-0.20" spread="2.84"/>
                    <measurement group_id="O3" value="1.41" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sleep Quality on the Pittsburgh Sleep Quality Index (PSQI) Total Score at Week 1</title>
        <description>The PSQI is an instrument to assess subjective sleep quality and disturbance. The Total score ranges from 0 to 21 where a lower score is better sleep quality. Change = (Week 1 score - Baseline score). Seven subscales (range 0-3) are summed to compute the Total score.</description>
        <time_frame>1 week</time_frame>
        <population>Seven participants who completed the double blind portion of the trial were unable to be analyzed for change in PSQI Total score due to incomplete PSQI questionnaire at baseline and/or Week 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Campral (Acamprosate)</title>
            <description>Acamprosate
Acamprosate: Total dose, 1998 mg daily, 1 week duration</description>
          </group>
          <group group_id="O2">
            <title>ReVia (Naltrexone)</title>
            <description>Naltrexone
Naltrexone: 50mg capsule, Once daily, 1 week duration</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill (Placebo)</title>
            <description>Placebo: Double-dummy placebo capsules, 1 week duration</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sleep Quality on the Pittsburgh Sleep Quality Index (PSQI) Total Score at Week 1</title>
          <description>The PSQI is an instrument to assess subjective sleep quality and disturbance. The Total score ranges from 0 to 21 where a lower score is better sleep quality. Change = (Week 1 score - Baseline score). Seven subscales (range 0-3) are summed to compute the Total score.</description>
          <population>Seven participants who completed the double blind portion of the trial were unable to be analyzed for change in PSQI Total score due to incomplete PSQI questionnaire at baseline and/or Week 1.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSQI Total Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" spread="3.14"/>
                    <measurement group_id="O2" value="4.74" spread="3.62"/>
                    <measurement group_id="O3" value="4.25" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSQI Total Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" spread="3.88"/>
                    <measurement group_id="O2" value="4.57" spread="3.55"/>
                    <measurement group_id="O3" value="4.38" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSQI Total Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="3.78"/>
                    <measurement group_id="O2" value="-0.17" spread="2.08"/>
                    <measurement group_id="O3" value="0.13" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Screening in Craving on the Alcohol Craving Questionnaire-Short Form (ACQ-SF) Total Score at Week 1</title>
        <description>The ACQ-SF is an assessment of current drinking urges, difficulty resisting urge and anticipation of positive outcome or relief from negative state by drinking. The Total score ranges from 0 to 7 where a lower score is a better outcome. Change = (Week 1 score - Screening score). The scale is comprised of twelve items (range 0-7) that are averaged to compute the Total score.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant in the naltrexone arm who completed the double blind portion of the trial was unable to be analyzed for change in ACQ-SF Total score due to incomplete ACQ-SF questionnaire at Week 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Campral (Acamprosate)</title>
            <description>Acamprosate
Acamprosate: Total dose, 1998 mg daily, 1 week duration</description>
          </group>
          <group group_id="O2">
            <title>ReVia (Naltrexone)</title>
            <description>Naltrexone
Naltrexone: 50mg capsule, Once daily, 1 week duration</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill (Placebo)</title>
            <description>Placebo: Double-dummy placebo capsules, 1 week duration</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Screening in Craving on the Alcohol Craving Questionnaire-Short Form (ACQ-SF) Total Score at Week 1</title>
          <description>The ACQ-SF is an assessment of current drinking urges, difficulty resisting urge and anticipation of positive outcome or relief from negative state by drinking. The Total score ranges from 0 to 7 where a lower score is a better outcome. Change = (Week 1 score - Screening score). The scale is comprised of twelve items (range 0-7) that are averaged to compute the Total score.</description>
          <population>One participant in the naltrexone arm who completed the double blind portion of the trial was unable to be analyzed for change in ACQ-SF Total score due to incomplete ACQ-SF questionnaire at Week 1.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACQ-SF Total Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="1.38"/>
                    <measurement group_id="O2" value="3.81" spread="1.55"/>
                    <measurement group_id="O3" value="3.99" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACQ-SF Total Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="1.28"/>
                    <measurement group_id="O2" value="3.69" spread="1.26"/>
                    <measurement group_id="O3" value="3.51" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACQ-SF Total Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="1.02"/>
                    <measurement group_id="O2" value="-0.12" spread="1.56"/>
                    <measurement group_id="O3" value="-0.48" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected at all four study visits, an average duration of 4 weeks.</time_frame>
      <desc>Adverse events, both serious and other, were documented at all four study visits by the Medical Assistant on the adverse event case report form.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acamprosate</title>
          <description>Acamprosate
Acamprosate: Total dose, 1998 mg daily, 1 week duration</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone</title>
          <description>Naltrexone
Naltrexone: 50mg capsule, Once daily, 1 week duration</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Double-dummy placebo capsules, 1 week duration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diaherrea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Decreased libido</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara J. Mason, Ph.D.-Principal Investigator</name_or_title>
      <organization>The Scripps Research Institute</organization>
      <phone>858784-7328</phone>
      <email>mason@scripps.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

